Yahoo · Sep 29, 2026
Palatin Technologies, Inc. Q4 2026 Earnings Call Summary
Moby summary of Palatin Technologies, Inc.'s Q4 2026 earnings call
PT
AMEX · PTN
Palatin Technologies, Inc.
Healthcare · Biotechnology
$5.00
Down-$0.01 (-0.20%)
Updated Nov 2, 2026, 10:17 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 641.56M
- P/E ratio
- -4.99
- Dividend yield
- 0.00%
- 52-week range
- $4.51 – $23.78
- Volume
- 16.04K
- Avg. volume
- 1.78M
Price performance · PTN
PTN price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
PTN closed at $5.00 after 20 trading sessions, down 47.26% for the selected period.
- Last close
- $5.00
- Period change
- -47.26%
- Period low
- $4.77
- Period high
- $9.52
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $4.93 | $5.105 | $4.895 | $5.00 | 16.04K |
| Oct 29, 2026 | $4.97 | $5.30 | $4.74 | $4.93 | 12.21K |
| Oct 28, 2026 | $4.65 | $5.17 | $4.51 | $5.10 | 42.46K |
| Oct 27, 2026 | $4.93 | $5.02 | $4.70 | $4.77 | 33.29K |
| Oct 26, 2026 | $5.10 | $5.42 | $4.58 | $4.82 | 28.08K |
| Oct 23, 2026 | $5.44 | $5.89 | $4.92 | $5.11 | 126.58K |
| Oct 22, 2026 | $5.7483 | $5.78 | $5.50 | $5.51 | 13.65K |
| Oct 21, 2026 | $5.60 | $5.85 | $5.40 | $5.55 | 20.48K |
| Oct 20, 2026 | $5.99 | $5.99 | $5.40 | $5.52 | 64.64K |
| Oct 19, 2026 | $6.03 | $6.45 | $5.55 | $5.99 | 56.38K |
| Oct 16, 2026 | $6.93 | $6.93 | $6.00 | $6.02 | 39.2K |
| Oct 15, 2026 | $7.40 | $8.00 | $6.35 | $6.49 | 43.42K |
| Oct 14, 2026 | $8.01 | $8.375 | $7.25 | $7.42 | 49.25K |
| Oct 13, 2026 | $8.93 | $9.07 | $8.135 | $8.19 | 14.21K |
| Oct 12, 2026 | $8.55 | $8.80 | $8.20 | $8.55 | 16.99K |
| Oct 9, 2026 | $8.93 | $9.20 | $8.375 | $8.60 | 31.44K |
| Oct 8, 2026 | $9.86 | $9.86 | $8.87 | $9.01 | 32.47K |
| Oct 7, 2026 | $9.87 | $9.87 | $9.1601 | $9.52 | 9.02K |
| Oct 6, 2026 | $9.00 | $9.88 | $9.00 | $9.41 | 2.77K |
| Oct 5, 2026 | $9.23 | $9.70 | $8.96 | $9.48 | 13.01K |
Latest PTN news
The latest Smart Investors Daily articles mentioning PTN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PTN research
Overview
Company profile and research snapshot.
Company profile
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. The Company's business is in one operating segment: life science.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $50.00
- Implied upside
- —
- Analysts
- 5
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 12, 2025 | Laidlaw & Co. | Buy | — |
| Feb 13, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 7, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 29, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 28, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Sep 28, 2026
Palatin Technologies, Inc. (PTN) Q4 2026 Earnings Call Transcript
Palatin Technologies, Inc. (PTN) Q4 2026 Earnings Call September 28, 2026 11:00 AM EDTCompany ParticipantsCarl Spana - Co-Founder, President, CEO &...
Yahoo · Sep 28, 2026
Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update
Palatin Technologies, Inc. (Nasdaq: PTN), a biopharmaceutical company developing medicines that target the melanocortin receptor ("MCR") system, today reported financial results for the fiscal year ended June 30, 2026 and provided an update on its MC4R-focused obesity development programs and partnering activities.
Benzinga · Sep 28, 2026
Palatin Techs Q4 EPS $(1.11) Up From $(2.73) YoY, Sales $300.770K
Palatin Techs (NASDAQ:PTN) reported quarterly losses of $(1.11) per share. This is a 59.34 percent increase over losses of $(2.73) per share from the same period last year. The company reported $300.770 thousand in
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
